These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Preliminary analysis of Huntington's Disease in South Korea. Shin CW; Choi YJ; Kim M; Jeon BS J Huntingtons Dis; 2013; 2(1):83-7. PubMed ID: 25063431 [TBL] [Abstract][Full Text] [Related]
6. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing. Ramos-Arroyo MA; Moreno S; Valiente A J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):337-42. PubMed ID: 15716522 [TBL] [Abstract][Full Text] [Related]
7. The Impact of Family History on the Clinical Features of Huntington's Disease. Kringlen G; Kinsley L; Aufox S; Rouleau G; Bega D J Huntingtons Dis; 2017; 6(4):327-335. PubMed ID: 28984613 [TBL] [Abstract][Full Text] [Related]
12. The number of CAG repeats within the normal allele does not influence the age of onset in Huntington's disease. Klempíř J; Zidovská J; Stochl J; Ing VK; Uhrová T; Roth J Mov Disord; 2011 Jan; 26(1):125-9. PubMed ID: 21322024 [TBL] [Abstract][Full Text] [Related]
13. Age of onset and behavioral manifestations in Huntington's disease: An Enroll-HD cohort analysis. Ranganathan M; Kostyk SK; Allain DC; Race JA; Daley AM Clin Genet; 2021 Jan; 99(1):133-142. PubMed ID: 33020896 [TBL] [Abstract][Full Text] [Related]
14. Weight loss in Huntington disease increases with higher CAG repeat number. Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for the onset and progression of Huntington disease. Chao TK; Hu J; Pringsheim T Neurotoxicology; 2017 Jul; 61():79-99. PubMed ID: 28111121 [TBL] [Abstract][Full Text] [Related]
16. Severity of cognitive impairment in juvenile and late-onset Huntington disease. Gómez-Tortosa E; del Barrio A; García Ruiz PJ; Pernaute RS; Benítez J; Barroso A; Jiménez FJ; García Yébenes J Arch Neurol; 1998 Jun; 55(6):835-43. PubMed ID: 9626775 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory Strategies for Huntington's Disease Treatment. Colpo GD; Rocha NP; Stimming EF; Teixeira AL CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048 [TBL] [Abstract][Full Text] [Related]
18. Effect of Apolipoprotein E Genotypes on Huntington's Disease Phenotypes in a Han Chinese Population. Li XY; Zhang YB; Xu M; Cheng HR; Dong Y; Ni W; Li HL; Wu ZY Neurosci Bull; 2019 Aug; 35(4):756-762. PubMed ID: 30887245 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of molecular testing in Huntington's disease. Wang V; Yeh TP; Chen CM; Yan SH; Soong BW Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):586-90. PubMed ID: 10502848 [TBL] [Abstract][Full Text] [Related]
20. Nonparametric modeling and analysis of association between Huntington's disease onset and CAG repeats. Ma Y; Wang Y Stat Med; 2014 Apr; 33(8):1369-82. PubMed ID: 24027120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]